• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards | Inspections
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
 
Trade NameACS 180/ADVIA CENTAUR AFP IMMUNOASSAY
Classification Namekit, test, alpha-fetoprotein for neural tube defects
Generic Nameafp immunoassy
ApplicantSIEMENS HEALTHCARE DIAGNOSTICS INC.
PMA NumberP930036
Supplement NumberS003
Date Received07/28/2005
Decision Date10/07/2005
Product Code
LOK[ Registered Establishments with LOK ]
Advisory Committee Immunology
Supplement Typereal-time process
Supplement Reason change design/components/specifications - other
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for the acs:180 and the centaur afp assays on the advia centaur cp system. The device, as modified, will be marketed under the trade name advia centaur cp afp and is indicated for in vitro diagnostic use in the quantitative determination of alpha-fetoprotein (afp) in 1) human serum and in amniotic fluid from specimens obtained at 15 and 20 weeks gestation, as an aid in detecting open neural tube defects (ntds) when used in conjunction with ultrasonography and amniography testing 2) human serum, as an aid in managing non-seminomatous testicular cancer when used in conjunction with physical examination, histology/pathology, and other clinical evaluation procedures, using the (bayer) system.
-
-